Cerus (NASDAQ:CERS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 30 percent increase over losses of $(0.10) per share from the same
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
According to data from Benzinga Pro, during Q4, Cerus's (NASDAQ:CERS) reported sales totaled $39.87 million. Despite a 26.66% increase in earnings, the company posted a loss of $9.12 million.
Cerus (NASDAQ:CERS) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Cerus beat estimated earnings by 37.5%, reporting an EPS of $-0.05 versus an estimate of $-0.08.